ArticleJournal of the International Association of Providers of AIDS Care
Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study.
Article in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Determinants of metabolic syndrome in people living with human immunodeficiency virus in Africa: a systematic review and meta-analysis.Frontiers in reproductive health · 2025Pooled it
- Longitudinal Weight Gain Trajectories After Initiation of Dolutegravir-Based Antiretroviral Therapy: A Retrospective Cohort Study.AIDS research and treatment · 2026Article
- Total cholesterol/high-density lipoprotein cholesterol ratio is a significant predictor of metabolic syndrome among people on dolutegravir-based antiretroviral therapy: A cross-sectional study in southwestern Uganda.The Journal of international medical research · 2025Article
- Prevalence and determinants of metabolic syndrome among adults living with HIV on first-line antiretroviral treatment in southern Ethiopia: a cross-sectional study.Therapeutic advances in chronic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens.
methodsA hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022.
resultsThe overall prevalence of metabolic syndrome was 18.6% (32/172) for all regimens, with 25.6% (22/86) for the DTG- and 11.6% (10/86) for the EFV-based regimens (
conclusionThe prevalence of metabolic syndrome was significantly higher among PLWH on DTG-based regimens. This signifies that DTG-treated patients should be advised on lifestyle adjustments to prevent the development of metabolic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.